Post-Covid, we all understand the importance of Biotechnology,
Biotech companies work day and night,
To develop state-of-the-art medicine and therapy.
And they require only one world-changing drug or therapy to shoot up in the billion-dollar market.
Today’s stock pick is one such biotech company.
Actinium Pharmaceuticals Inc (ATNM)
Actinium Pharmaceuticals is developing targeted radiotherapies that deliver cancer-killing radiation with cellular-level precision.
What makes Actinium Pharmaceuticals Stand out?
The treatment Actinium Pharmaceuticals is working on targets patients who have significant needs that are not being satisfied by current cancer therapies.
Chemotherapy is not able to kill off enough cancer cells, hence chances of it coming back are always there. This is where Actinium harmaceuticals targeted radiotherapy comes in.
5 Reasons to Strongly Consider Actinium Pharmaceuticals
There is demand for Leukemia cures and the market for it can reach %17.1 billion by 2024. A wide-open opportunity for Actinium Pharmaceuticals.
Actinium Pharmaceutical’s Iomab-B could be nearing a treatment with SIERRA trials showing 5 times better results on patients.
Actinium Pharmaceutical’s trial is the ONLY randomized phase 3 trial to offer Bone Marrow Transplant (BMT) which is potentially the only cure for Leukemia.
Actinium Pharmaceuticals is strengthening its patent internationally as the company can sense they are one step closer to a revolutionary breakthrough.
Analysts are going crazy over the potential Actinium Pharmaceuticals stock has to go big.
Biotech Companies = High-Reward Stocks
According to previous experience, when biotech companies discover a cure, the consequences can be life-changing.
Clinical trial news can drastically affect share prices. One such example from 2004 can be seen in the chart below.
See how the Genetech stock went boom after succeeding in trials?
Keep a watch on Actinium Pharmaceuticals as its Iomab-B therapy advances through the Phase III SIERRA trials with more than promising results.
Meanwhile, the phase II results below show the overall survival rate of patients going under their treatment to be far more than conventional treatment-receiving patients.
If things continue progressing the way they are, Actinium Pharmaceuticals (NYSE: ATNM) could be a game-changer.
Financial Conditions and Outlook
Actinium Pharmaceuticals seems to be financially comfortable carrying out its expeditions for the next few years.
It possesses Cash and cash equivalents of approximately $116.3 million as of June 30, 2022, including a $35 million upfront payment from Iomab-B EUMENA licensing agreement with Immedica AB,
Furthermore, Actinium Pharmaceuticals anticipates that its current cash and cash equivalents will be sufficient to fund operations through mid-2025.
Actinium Pharmaceuticals in the News
As always, I would recommend that you do your own research starting from here.
Let’s learn and earn together 💪!
Team Inspired Analyst - Signing off.
Disclaimer
This sponsored post references an opinion and is for information purposes only. It is not intended to be investment/financial advice. Seek a duly licensed professional for investment/financial advice. Please always do your research before investing as you are responsible for any capital-related decisions you make and only you are accountable for the results.
ATNM is shariah non-compliant according to Zoya. I do appreciate the stock idea.